PCSK9 Cholesterol Drugs And FDA’s Missing Mandatory Study Authority
This article was originally published in The Pink Sheet Daily
FDA advisory committee seems conflicted about when LDL-lowering can be fully valid surrogate endpoint, but issue would probably be a lot simpler for FDA – and sponsors – if FDA had authority to mandate trials for efficacy.
You may also be interested in...
Sponsors of injectable PCSK9 biologics address questions about the implications of the IMPROVE-IT study, in which the soon-to-be-generic oral Zetia helped bring down LDL cholesterol to a very low level.
Has there ever been a Presidential address on drug pricing that included so much substance and yet caused so little reaction as President Biden’s Dec. 6 White House speech on the topic?
Robert Califf’s first tenure as US FDA Commissioner was decidedly anti-climactic. His return trip – assuming the Senate confirms him – will be potentially transformational: he will be the leader that defines what FDA is after COVID.